Swiss Semiconductors Stock News

Bossard Holding (SWX:BOSN) FY 2025 Results Set the Tone for Margins and Growth Expectations Bossard Holding (SWX:BOSN) opened FY 2025 with first half revenue of CHF547.9 million and net income of CHF37.4 million, setting a clear earnings benchmark for investors watching how profits track through the rest of the year. The company reported revenue of CHF509.4 million and net income of CHF41.3 million in the first half of 2024, followed by CHF477.0 million and CHF31.1 million in the second half...

Latest FY 2025 headline numbers V-ZUG Holding (SWX:VZUG) has opened FY 2025 with first half revenue of CHF 271.2 million and basic EPS of CHF 0.25, setting a cautious tone around profitability and growth. The company has seen revenue move from CHF 284.1 million in 1H 2024 to CHF 307.6 million in 2H 2024, with EPS shifting from CHF 1.36 to CHF 1.97 over the same periods, before settling at CHF 0.25 in the latest half. This leaves investors focused squarely on how margins are holding up through...

Idorsia reports recent commercial traction for its insomnia drug Quvivic, including broader public reimbursement across major European and North American markets. The company highlights plans for further international rollout of Quvivic and updates on late stage pipeline assets, including pediatric studies. Partnered programs are progressing clinically, with collaborations moving forward alongside Idorsia’s own R&D efforts. Idorsia (SWX:IDIA) is drawing attention as it updates investors on...

European Medicines Agency’s CHMP issues a positive opinion on remibrutinib for adults with chronic spontaneous urticaria who do not respond adequately to standard therapies. CHMP recommendation is based on clinical trial data and represents a key regulatory step for SWX:NOVN in allergic and immunological conditions. Novartis announces plans for a new radioligand therapy manufacturing site in Texas to support production of cancer therapies in the US. Novartis, traded as SWX:NOVN, is a large...

If you are wondering whether Sandoz Group is still attractively priced after its recent run, this article will help you size up what you are really paying for each Swiss franc of the business. The shares closed at CHF64.66, with a 7.0% return over the last month, a 13.0% return year to date, and a 71.1% return over the past year, although the last 7 days saw an 8.1% decline that may have changed how some investors view the risk and reward trade off. Recent news flow around Sandoz Group has...

Galderma Group (SWX:GALD) reports full year sales above $5b, marking a milestone for its dermatology focused portfolio. The company highlights new product launches it describes as having blockbuster potential across its prescription and aesthetics segments. Fresh clinical data show Nemluvio delivering long term efficacy and safety in prurigo nodularis, an area of high unmet medical need. Regulatory approval of new device technology supports further expansion of Galderma's aesthetics...

Adecco Group (SWX:ADEN) shares are in focus after the company reported fourth quarter and full year 2025 results, along with upcoming Board changes that include planned departures and a defined end date for the current Chair. See our latest analysis for Adecco Group. The earnings and Board updates come after a weaker share price patch, with a 1-day share price return of 2.03% at CHF21.06, compared with a year-to-date share price return of 10.23% and a 1-year total shareholder return of...

How VAT Group’s FY 2025 Numbers Set Up the Next Chapter VAT Group (SWX:VACN) has wrapped up FY 2025 with second half revenue of CHF 515.6 million and basic EPS of CHF 3.63, alongside trailing twelve month revenue of CHF 1.07 billion and EPS of CHF 7.15 framing the latest print. Over recent periods, the company has seen half yearly revenue move from CHF 492.6 million in 2H 2024 to CHF 515.6 million in 2H 2025, while half yearly EPS shifted from CHF 3.92 to CHF 3.63, and trailing twelve month...

What the latest earnings tell you about Zug Estates Holding Zug Estates Holding (SWX:ZUGN) just released full year 2025 figures, with sales of CHF 87.72 million, revenue of CHF 91.5 million, and net income of CHF 85.18 million drawing fresh investor attention. These headline numbers give you a fresh reference point for thinking about the stock, its current valuation, and how the business is converting its real estate and hotel activities into bottom line results. See our latest analysis for...

HIAG Immobilien Holding FY 2025 earnings snapshot HIAG Immobilien Holding (SWX:HIAG) has just posted its FY 2025 numbers, with first half revenue of CHF 47.6 million and basic EPS of CHF 4.42, while funds from operations came in at CHF 1.90 per share, giving investors a fresh read on both cash generation and headline profitability. Over recent periods the company has seen revenue move from CHF 70.3 million in the first half of 2024 to CHF 65.8 million in the second half of 2024 and then to...

What Holcim’s 2025 earnings mean for shareholders Holcim (SWX:HOLN) has moved into focus after reporting full year 2025 results, with sales of CHF 15,724 million compared to CHF 16,201 million a year earlier, and a sharp jump in reported net income and earnings per share. See our latest analysis for Holcim. Despite the strong headline earnings, Holcim’s 1 month share price return of an 18.15% decline and a 14% share price pullback year to date suggest momentum has cooled, even as the 1 year...

Implenia (SWX:IMPN) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 1.9b and basic EPS of CHF 1.80 setting the tone for how the year is shaping up. The company has seen revenue move from CHF 1.7b in the first half of 2024 to CHF 1.9b in the latest half, while basic EPS shifted from CHF 1.43 to CHF 1.80 over the same periods, creating a results season in which investors are weighing growth prospects against how efficiently those sales are turning into profit. See...

What Swisscom’s Recent Share Performance Tells You Swisscom (SWX:SCMN) has seen its share price move in recent weeks, with a 0.8% decline over the past day contrasting with gains over the past week, month and past 3 months. For context, the stock shows a 0.9% return over the past week, 12.3% over the past month and 28.2% over the past 3 months, with a 45.7% total return over the past year. See our latest analysis for Swisscom. The recent pullback in Swisscom’s share price to CHF714.5 comes...

Roche Holding (SWX:ROG) is back in focus after Genentech reported that fenebrutinib met the primary endpoint in the pivotal Phase III FENhance 1 trial in relapsing multiple sclerosis, with statistically significant efficacy versus teriflunomide. See our latest analysis for Roche Holding. The fenebrutinib update lands after a series of drug pipeline milestones and conference appearances. It comes with a 90 day share price return of 15.7% and a 1 year total shareholder return of 22.3%, which...

Amrize (SWX:AMRZ) has introduced its new EVERtect™ high-performance concrete range for customers in North America. The portfolio includes multiple specialized mixes tailored for different construction uses across the U.S. and Canada. The launch expands Amrize’s presence in high-spec concrete solutions for both structural and low-carbon applications. For you as an investor, this move highlights how Amrize is positioning its core materials business around more differentiated, higher-spec...

If you are wondering whether ABB's current share price still makes sense after a strong run, this article breaks down what you are really paying for the business today. ABB shares last closed at CHF 67.20, with returns of 46.1% over 1 year and 181.5% over 5 years. The shorter term picture is mixed, with a 4.8% decline over 7 days but a 9.7% gain year to date. Recent headlines have focused on ABB's ongoing position as a major player in electrification and automation, as well as its exposure...

Alcon reports that more than 175 million of its intraocular lenses have been implanted worldwide. The milestone highlights broad adoption of the company’s presbyopia-correcting IOLs across global eye care practices. Alcon plans further intraocular lens launches, subject to regulatory approvals. For investors following Alcon (SWX:ALC), this update comes with the shares trading at CHF63.96 and a value score of 4. The stock shows a 22.3% decline over the past year, while 3-year and 5-year...

On 24 February 2026, Iconovo AB announced it had signed a Letter of Intent with Lonza Group to pursue a long-term collaboration around spray dried formulation capabilities for inhalable biologics, building on their existing work on an obesity project. This potential alliance links Lonza’s CDMO scale with Iconovo’s five-platform inhaler technology targeting biologics and high-value respiratory franchises with global turnover of about US$9.00 billion. We’ll now examine how this focus on spray...

Avolta AG recently completed the cancellation of about 4.9 million treasury shares, reducing its registered share capital to CHF 708,241,695 across 141,648,339 shares, while continuing to expand its food and beverage footprint at key airports in Italy and Canada. This combination of a tighter share base and integrated travel retail and dining growth highlights Avolta’s focus on capital efficiency alongside strengthening its airport partner relationships. Next, we’ll examine how Avolta’s...

Zurich Insurance Group has confirmed the acquisition of UK based insurer Beazley, following completion of an accelerated equity offering to fund the deal. The transaction expands Zurich's presence in international insurance markets and follows investor backing via fresh equity capital. The company, trading as SWX:ZURN, remains in focus as integration plans and capital impacts come into view for shareholders. Zurich Insurance Group, ticker SWX:ZURN, is approaching this deal with a current...

Sandoz Group (SWX:SDZ) has received EU marketing authorization for Ranluspec. The approval expands the company’s biosimilars portfolio into the ophthalmology segment. The decision supports an expected product launch later in 2026 across European markets. For you as an investor, this represents a business development in a high-value area of medicine. Sandoz focuses on biosimilars and generics, and Ranluspec adds another product aimed at chronic eye conditions where long-term treatment is...

Why the infant formula recalls matter for Nestlé (SWX:NESN) Nestlé (SWX:NESN) is under close watch after recalling infant formula products in more than 60 countries due to low levels of the cereulide toxin, prompting tighter safety controls and raising fresh questions for shareholders about risk and resilience. See our latest analysis for Nestlé. Despite concerns around the recalls, Nestlé’s recent 30 day share price return of 13.32% and year to date share price return of 8.86% contrast with...

Recent commentary around rapid growth in digital mining, particularly for lithium and copper related to electric vehicles and the energy transition, has put ABB (SWX:ABBN) in focus as it expands partnerships and mining technologies. See our latest analysis for ABB. Against this backdrop of digital mining partnerships and technology deployments, ABB’s share price sits at CHF70.64, with a 90 day share price return of 22.98% and a 1 year total shareholder return of 47.76%. This suggests momentum...

Why Novartis is on investors’ radar today Novartis (SWX:NOVN) is in focus for investors after a strong run recently, with the share price showing double digit returns over the past month and the past 3 months. This performance is prompting closer attention to valuations. See our latest analysis for Novartis. Looking beyond the recent surge, Novartis’ share price is now at CHF130.5, with a 30 day share price return of 13.85% and a year to date share price return of 20.28%. The 1 year total...